Short Interest in Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Declines By 42.1%

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) saw a significant drop in short interest during the month of April. As of April 15th, there was short interest totalling 14,600 shares, a drop of 42.1% from the March 31st total of 25,200 shares. Based on an average daily volume of 66,800 shares, the days-to-cover ratio is currently 0.2 days.

Shionogi & Co., Ltd. Trading Up 2.1 %

Shares of OTCMKTS SGIOY traded up $0.24 during trading hours on Friday, hitting $11.65. The company's stock had a trading volume of 89,694 shares, compared to its average volume of 65,489. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.03 and a current ratio of 5.47. The stock has a market cap of $14.32 billion, a price-to-earnings ratio of 12.39, a P/E/G ratio of 1.80 and a beta of 0.22. Shionogi & Co., Ltd. has a 12 month low of $10.10 and a 12 month high of $13.67. The business has a 50-day simple moving average of $12.39 and a 200-day simple moving average of $12.06.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY - Get Free Report) last posted its earnings results on Wednesday, January 31st. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.11). The business had revenue of $719.72 million during the quarter. Shionogi & Co., Ltd. had a return on equity of 12.90% and a net margin of 36.27%. On average, analysts anticipate that Shionogi & Co., Ltd. will post 0.93 earnings per share for the current fiscal year.

About Shionogi & Co., Ltd.

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.